Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy
Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1
Dyne Therapeutics Announces Submission of Biologics License Application to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy Ahead of Planned BLA Submission for U.S. Accelerated Approval
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE Platform at 2026 ASGCT Annual Meeting
SAGA Metals Reports Assays from R-0058 to R-0060 with Intercepts Including 43.86% Fe2O3, 6.10% TiO2, 0.317% V2O5 from 2026 Drilling at Radar Critical Minerals Project in Labrador and Adds to Its Advisory Board
